Search
Aboriginal health is everyone's business. The needs of Aboriginal and Torres Strait Islander families and kids is integrated into all relevant areas of our work. Improving the health and wellbeing of Aboriginal and Torres Strait Islander kids and families is an overarching priority for every team at The Kids.
Head, Strep A Translation; Co-Founder of REACH
As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story
New research has revealed that molecular point-of-care testing (POCT) can significantly improve detection of Group A Streptococcal (Strep A) pharyngitis compared to laboratory culture – particularly in remote communities, where results can take up to seven days – unlocking a major opportunity to prevent rheumatic
A team led by Dr Joseph Kado from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and The University of Western Australia (UWA) has been awarded $5 million by the Federal Government in a major push to prevent rheumatic heart disease across the Pacific.
Instant diagnosis and treatment of potentially life-threatening Strep A infections is now very close to reality across Australia’s remote and regional areas thanks to molecular point-of-care testing (POCT) that slashes result times from five days to just minutes.
There are calls for a significant and urgent injection of $40 million in funding to tackle Rheumatic Heart Disease (RHD) following Monday night’s Four Corners episode.
This research sought to provide an outline of identified household-level environmental health initiatives to reduce or interrupt Strep A transmission along each of these pathways.
We explore the contemporary landscape of housing investments and initiatives seeking to improve health outcomes among Aboriginal and Torres Strait Islander people in Australia, as well as the dearth of quality evidence and agreed approaches to evaluation.
Monthly intramuscular injections of benzathine penicillin G (BPG) remain the cornerstone of secondary prophylaxis for acute rheumatic fever and rheumatic heart disease (RHD). The barriers to successful delivery of BPG may be patient- or service-delivery-dependent.